| Complication | Evidence | PMID |
| Nephropathy | 1. The risk of developing DN is significantly enhanced in IL1B T allele carriers (dominant model, p=0.005) and in homozygotes (additive model, p=0.018) respectively. However, the recessive model for T allele (p=0.097) and the co-dominant model (p=0.085) produced non-significant . Considering that the additive model was significant (OR=2. 53, 95% CI=1.20-5.36) and the co-dominant is non-significant (OR=1.53, 95% CI=0.97-2. 40), the mode of inheritance is complete "additiveness," with the degree of dominance being h=0. The findings provided evidence that the IL1B C-511T variant might be associated with development of DN | 24839897 |
| Cardiovascular | 1. We assessed at baseline, at the end of Phase A, and at the end of Phase B the levels of some new emerging biomarkers of cardiovascular risk includinghigh sensitivity C-reactive protein (Hs-CRP), adiponectin (ADN), tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), myeloperoxidase (MPO), soluble CD40 ligand (sCDL40). | 26223257 |
| Retinopathy | 1. The inflammatory cytokines and angiogenic factors IL1B, IL6, IL8, CCL2, EDN1, VEGF, and TNF are increased in the vitreous of PDR patients without an increase in IL-10. These add support to the role of inflammatory cytokines and angiogenic factors in the genesis of PDR | 22409294 |
| Tuberculosis | 1. Tuberculosis with diabetes is characterized by elevated circulating levels of type 1 (IFN-?, tumor necrosis factor-?, and IL-2), type 2 (IL-5), and type 17 (IL-17A) cytokines but decreased circulating levels of IL-22. This was associated with increased systemic levels of other pro-inflammatory cytokines (IL-1?, IL-6, and IL-18) and an anti-inflammatory cytokine (IL-10) but not type 1 IFNs. | 23987505 |
| Insulin resistance and inflammation | 1. Here we show a pronounced proinflammatory signature of adipose tissue macrophages in type 2 diabetic obese patients, mainly driven by increased NLRP3-dependent interleukin (IL)-1? production. IL-1? release increased with glycemic deterioration and decreased after gastric bypass surgery. | 24520123 |
